Biological markers and Alzheimer disease: A Canadian perspective

International Journal of Alzheimer's Disease

Volumn , Issue , 2010, Pages

  Schipper, Hyman M ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA AMYLOID[1 42]; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CANADA; DISEASE COURSE; FAMILY COUNSELING; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

EID: 77956841547     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.4061/2010/978182     Document Type: Review

References (76)

1. Schipper H. M., The role of biologic markers in the diagnosis of Alzheimer's disease Alzheimer's and Dementia 2007 3 4 325 332
2. Consensus report of the working Group on "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group Neurobiology of Aging 1998 19 2 109 116
3. Schipper H. M., Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiology of Aging. In press
4. Klunk W. E., Biological markers of Alzheimer's disease Neurobiology of Aging 1998 19 2 145 147
5. Frank R. A., Galasko D., Hampel H., Hardy J., De Leon M. J., Mehta P. D., Rogers J., Siemers E., Trojanowski J. Q., Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease Neurobiology of Aging 2003 24 4 521 536
6. Burns D. H., Rosendahl S., Bandilla D., Maes O. C., Chertkow H. M., Schipper H. M., Near-infrared spectroscopy of blood plasma for diagnosis of sporadic alzheimer's disease Journal of Alzheimer's Disease 2009 17 2 391 397
7. Peuchant E., Richard-Harston S., Bourdel-Marchasson I., Dartigues J.-F., Letenneur L., Barberger-Gateau P., Arnaud-Dabernat S., Daniel J.-Y., Infrared spectroscopy: a reagent-free method to distinguish Alzheimer's disease patients from normal-aging subjects Translational Research 2008 152 3 103 112
8. Craig-Schapiro R., Fagan A. M., Holtzman D. M., Biomarkers of Alzheimer's disease Neurobiology of Disease 2009 35 2 128 140
9. Lee K. S., Chung J. H., Choi T. K., Suh S. Y., Oh B. H., Hong C. H., Peripheral cytokines and chemokines in Alzheimer's disease Dementia and Geriatric Cognitive Disorders 2009 28 4 281 287
10. Leoni V., Oxysterols as markers of neurological diseasea review Scandinavian Journal of Clinical and Laboratory Investigation 2009 69 1 22 25
11. Mangialasche F., Polidori M. C., Monastero R., Ercolani S., Camarda C., Cecchetti R., Mecocci P., Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment Ageing Research Reviews 2009 8 4 285 305
12. Perrin R. J., Fagan A. M., Holtzman D. M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease Nature 2009 461 7266 916 922
13. Schneider P., Hampel H., Buerger K., Biological marker candidates of Alzheimer's disease in blood, plasma, and serum CNS Neuroscience and Therapeutics 2009 15 4 358 374
14. Shi M., Caudle W. M., Zhang J., Biomarker discovery in neurodegenerative diseases: a proteomic approach Neurobiology of Disease 2009 35 2 157 164
15. Song F., Poljak A., Smythe G. A., Sachdev P., Plasma biomarkers for mild cognitive impairment and Alzheimer's disease Brain Research Reviews 2009 61 2 69 80
16. Maes O. C., Xu S., Yu B., Chertkow H. M., Wang E., Schipper H. M., Transcriptional profiling of Alzheimer blood mononuclear cells by microarray Neurobiology of Aging 2007 28 12 1795 1809
17. Schipper H. M., Maes O. C., Chertkow H. M., Wang E., MicroRNA expression in Alzheimer blood mononuclear cells Gene Regulation Systems Biology 2007 1 263 274
18. Schipper H. M., Biomarker potential of heme oxygenase-1 in Alzheimer disease and mild cognitive impairment Biomarkers in Medicine 2007 1 375 385
19. Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nature Reviews Neurology 2010 6 3 131 144
20. Shoji M., Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness Frontiers in Bioscience 2002 7 997 1006
21. Sunderland T., Linker G., Mirza N., Putnam K. T., Friedman D. L., Kimmel L. H., Bergeson J., Manetti G. J., Zimmermann M., Tang B., Bartko J. J., Cohen R. M., Decreased -amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease Journal of the American Medical Association 2003 289 16 2094 2103
22. Blennow K., Hampel H., CSF markers for incipient Alzheimer's disease Lancet Neurology 2003 2 10 605 613
23. Mollenhauer B., Cepek L., Bibl M., Wiltfang J., Schulz-Schaeffer W. J., Ciesielczyk B., Neumann M., Steinacker P., Kretzschmar H. A., Poser S., Trenkwalder C., Otto M., Tau protein, A 42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies Dementia and Geriatric Cognitive Disorders 2005 19 2-3 164 170 (Pubitemid 40868045)
24. Clark C. M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., Morris J. C., McKeel D. W. Jr., Farlow M., Weitlauf S. L., Quinn J., Kaye J., Knopman D., Arai H., Doody R. S., DeCarli C., Leight S., Lee V. M.-Y., Trojanowski J. Q., Cerebrospinal fluid tau and -Amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of Neurology 2003 60 12 1696 1702
25. Gmez-Tortosa E., Gonzalo I., Fanjul S., Sainz M. J., Cantarero S., Cemilln C., Garca Ybenes J., Del Ser T., Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease Archives of Neurology 2003 60 9 1218 1222 (Pubitemid 37099626)
26. Sjgren M., Andreasen N., Blennow K., Advances in the detection of Alzheimer's diseaseuse of cerebrospinal fluid biomarkers Clinica Chimica Acta 2003 332 1-2 1 10
27. Holmberg B., Johnels B., Blennow K., Rosengren L., Cerebrospinal fluid A 42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy Movement Disorders 2003 18 2 186 190
28. Otto M., Esselmann H., Schulz-Schaeffer W., Neumann M., Schrter A., Ratzka P., Cepek L., Zerr I., Steinacker P., Windl O., Kornhuber J., Kretzschmar H. A., Poser S., Wiltfang J., Decreased -amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurology 2000 54 5 1099 1102
29. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H. C., Riemenschneider M., De Deyn P. P., Bancher C., Cras P., Wiltfang J., Mehta P. D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H., Improved discrimination of AD patients using -amyloid 1-42 and tau levels in CSF Neurology 1999 52 8 1555 1562
30. Trojanowski J. Q., Lee V. M.-Y., Commentary on "Diagnosis of Alzheimer's disease: two decades of progress" Alzheimer's disease research: new opportunities for early diagnosis and drug discovery Alzheimer's and Dementia 2005 1 2 119 120
31. Petersen R. C., Aisen P. S., Beckett L. A., Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology 2010 74 3 201 209
32. Iwatsubo T., Amyloid protein in plasma as a diagnostic marker for Alzheimer's disease Neurobiology of Aging 1998 19 2 161 163
33. Olsson A., Hglund K., Sjgren M., Andreasen N., Minthon L., Lannfelt L., Buerger K., Mller H.-J., Hampel H., Davidsson P., Blennow K., Measurement of -and -secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients Experimental Neurology 2003 183 1 74 80
34. Mehta P. D., Pirttil T., Mehta S. P., Sersen E. A., Aisen P. S., Wisniewski H. M., Plasma and cerebrospinal fluid levels of amyloid proteins 1-40 and 1-42 in Alzheimer disease Archives of Neurology 2000 57 1 100 105
35. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., Shoji S., Amyloid protein in plasma from patients with sporadic Alzheimer' s disease Journal of the Neurological Sciences 1996 141 1-2 65 68
36. Lewczuk P., Esselmann H., Groemer T. W., Bibl M., Maler J. M., Steinacker P., Otto M., Kornhuber J., Wiltfang J., Amyloid peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease Biological Psychiatry 2004 55 5 524 530
37. Maruyama M., Matsui T., Tanji H., Nemoto M., Tomita N., Ootsuki M., Arai H., Sasaki H., Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways Archives of Neurology 2004 61 5 716 720
38. Green A. J. E., Harvey R. J., Thompson E. J., Rossor M. N., Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease Neuroscience Letters 1999 259 2 133 135
39. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K., Sensitivity, specificity, and stability of CSF-tau in AD in a community- based patient sample Neurology 1999 53 7 1488 1494
40. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., Blennow K., Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke Journal of Alzheimer's Disease 2000 2 3-4 199 206
41. Leszek J., Mayszczak K., Janicka B., Kiejna A., Wiak A., Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia Medical Science Monitor 2003 9 11 CR484 CR488
42. Grossman M., Farmer J., Leight S., Work M., Moore P., Van Deerlin V., Pratico D., Clark C. M., Coslett H. B., Chatterjee A., Gee J., Trojanowski J. Q., Lee V. M.-Y., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease Annals of Neurology 2005 57 5 721 729 (Pubitemid 40628861)
43. Schnknecht P., Pantel J., Hunt A., Volkmann M., Buerger K., Hampel H., Schrder J., Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease Neuroscience Letters 2003 339 2 172 174
44. Buerger K., Teipel S. J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H.-J., Davies P., Hampel H., CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects Neurology 2002 59 4 627 629
45. Arai H., Ishiguro K., Ohno H., Moriyama M., Itoh N., Okamura N., Matsui T., Morikawa Y.-I., Horikawa E., Kohno H., Sasaki H., Imahori K., CSF phosphorylated tau protein and mild cognitive impairment: a prospective study Experimental Neurology 2000 166 1 201 203
46. De Leon M. J., Desanti S., Zinkowski R., Mehta P. D., Pratico D., Segal S., Clark C., Kerkman D., Debernardis J., Li J., Lair L., Reisberg B., Tsui W., Rusinek H., MRI and CSF studies in the early diagnosis of Alzheimer's disease Journal of Internal Medicine 2004 256 3 205 223 (Pubitemid 39222990)
47. Hampel H., Buerger K., Zinkowski R., Teipel S. J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Mller H.-J., Davies P., Blennow K., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Archives of General Psychiatry 2004 61 1 95 102
48. Lewczuk P., Esselmann H., Bibl M., Beck G., Maler J. M., Otto M., Kornhuber J., Wiltfang J., Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature Journal of Molecular Neuroscience 2004 23 1-2 115 122
49. Vanmechelen E., Vanderstichele H., Davidsson P., Van Kerschaver E., Van Der Perre B., Sjgren M., Andreasen N., Blennow K., Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization Neuroscience Letters 2000 285 1 49 52
50. Schoonenboom N. S. M., Pijnenburg Y. A. L., Mulder C., Rosso S. M., Van Elk E.-J., Van Kamp G. J., Van Swieten J. C., Scheltens PH., Amyloid (1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease Neurology 2004 62 9 1580 1584
51. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F., CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies Neurological Sciences 2001 22 1 77 78
52. Kurz A., Riemenschneider M., Wallin A., Potential biological markers for cerebrovascular disease International Psychogeriatrics 2003 15 supplement 1 89 97
53. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E., tau Protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Molecular and Chemical Neuropathology 1995 26 3 231 245
54. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neuroscience Letters 2001 297 3 187 190
55. Schnknecht P., Hempel A., Hunt A., Seidl U., Volkmann M., Pantel J., Schrder J., Cerebrospinal fluid tau protein levels in schizophrenia European Archives of Psychiatry and Clinical Neuroscience 2003 253 2 100 102
56. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Frstl H., Kurz A., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias Molecular Psychiatry 2003 8 3 343 347
57. Goodall C. A., Head M. W., Everington D., Ironside J. W., Knight R. S. G., Green A. J. E., Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications Journal of Neurology, Neurosurgery and Psychiatry 2006 77 1 89 91
58. Blennow K., Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 2004 1 2 213 225
59. Wahlund L.-O., Blennow K., Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients Neuroscience Letters 2003 339 2 99 102
60. Ganzer S., Arlt S., Schoder V., Buhmann C., Mandelkow E.-M., Finckh U., Beisiegel U., Naber D., Mller-Thomsen T., CSF-tau, CSF-A 1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity Journal of Neural Transmission 2003 110 10 1149 1160
61. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., Kurz A., Cerebrospinal fluid tau and -amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Archives of Neurology 2002 59 11 1729 1734
62. Hampel H., Teipel S. J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Mller H.-J., Blennow K., Buerger K., Value of CSF -amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Molecular Psychiatry 2004 9 7 705 710
63. Herukka S.-K., Hallikainen M., Soininen H., Pirttil T., CSF A 42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment Neurology 2005 64 7 1294 1297
64. Ivanoiu A., Sindic C. J. M., Cerebrospinal fluid TAU protein and amyloid 42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination Neurocase 2005 11 1 32 39
65. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.-K., Van Der Flier W. M., Blankenstein M. A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosn E., Aarsland D., Jelle Visser P., Schrder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Pirttil T., Wallin A., Eriksdotter Jnhagen M., Minthon L., Winblad B., Blennow K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Journal of the American Medical Association 2009 302 4 385 393
66. Visser P. J., Verhey F., Knol D. L., Scheltens P., Wahlund L.-O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin A. K., Hampel H., Brger K., Pirttila T., Soininen H., Rikkert M. O., Verbeek M. M., Spiru L., Blennow K., Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study The Lancet Neurology 2009 8 7 619 627
67. Klunk W. E., Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking? Neurobiology of Aging 2002 23 4 517 519
68. Peskind E. R., Riekse R., Quinn J. F., Kaye J., Clark C. M., Farlow M. R., Decarli C., Chabal C., Vavrek D., Raskind M. A., Galasko D., Safety and acceptability of the research lumbar puncture Alzheimer Disease and Associated Disorders 2005 19 4 220 225
69. Chertkow H., Introduction: the third Canadian consensus conference on the diagnosis and treatment of dementia, 2006 Alzheimer's and Dementia 2007 3 4 262 265
70. The AGREE Collaboration: Appraisal of guidelines for research and evaluation [AGREE] instrument, 2001, www.agreecollaboration.org
71. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J. M., Gavaghan D. J., McQuay H. J., Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996 17 1 1 12
72. Woolf S. H., Battista B. N., Anderson G. M., Logan A. G., Wang E., Goldbloom R. B., Beaulieu M.-D., Feightner J. W., Feldman W., Mann K. V., Mickelson P., Morrison B. J., Offord D., Patterson C., Spitzer W. O., Haggerty J., Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on Periodic Health Examination Journal of Clinical Epidemiology 1990 43 9 891 905
73. Patterson C. J. S., Gauthier S., Bergman H., Cohen C. A., Feightner J. W., Feldman H., Hogan D. B., The recognition, assessment and management of dementing disorders: conclusions from the Canadian consensus conference on dementia Canadian Medical Association Journal 1999 160 12 S1 S15
74. Patterson C. J. S., Gauthier S., Bergman H., Cohen C. A., Feightner J. W., Feldman H., Hogan D. B., Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations Canadian Medical Association Journal 1999 160 12 1738 1742
75. Choe L. H., Dutt M. J., Relkin N., Lee K. H., Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease Electrophoresis 2002 23 14 2247 2251
76. Yu H.-L., Chertkow H. M., Bergman H., Schipper H. M., Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma Proteomics 2003 3 11 2240 2248